In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her‐2/neu binding sites
- 8 May 2014
- journal article
- research article
- Published by Wiley in Biotechnology Journal
- Vol. 9 (6), 844-851
- https://doi.org/10.1002/biot.201300387
Abstract
Antigen‐binding Fc fragments (Fcabs) are a new unique class of immunotherapeutics. They are small (50 kD) fully functional antibody alternatives that bind antigen and elicit effector functions such as antibody‐dependent cytotoxicity (ADCC) and complement‐dependent cytotoxicity. Since Fcabs carry the natural FcRn binding site of antibodies, they have very favorable pharmacokinetics. We showed recently that Fcab H10‐03‐6 is a high‐affinity binder of Her‐2/neu (ErbB2/neu) mediating killing of Her‐2/neu‐overexpressing tumor cells in the presence of immune effector cells, strongly suggesting that the mechanism of killing is due to ADCC. The present study further confirms ADCC as the mechanism by which H10‐03‐6 mediates tumor cell killing, since H10‐03‐6 was shown to interact simultaneously with Her‐2/neu and the Fc receptor CD16a. The epitope recognized by H10‐03‐6 overlaps with that of the clinically used monoclonal antibody trastuzumab. However, unlike trastuzumab, Fcab H10‐03‐6 did not inhibit proliferation of human tumor cells in vitro even under conditions favoring Her‐2/neu crosslinking. Treatment of mice harboring human BT‐474 cell xenograft tumors with Fcab H10‐03‐6 led to statistically significant retardation of tumor growth. For the first time, in vivo properties of an Fcab are presented, supporting the view that Fcabs could become highly efficacious immunotherapeutics for human use.Keywords
Funding Information
- Christian Doppler Research Association
- F-star
- Laura Bassi Centres of Expertise (822757)
This publication has 23 references indexed in Scilit:
- Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsJournal of Translational Medicine, 2013
- Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab)Archives of Biochemistry and Biophysics, 2012
- Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody propertiesProtein Engineering, Design and Selection, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significanceZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancerAnnals of Oncology, 2007
- Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCancer Immunology, Immunotherapy, 2005
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.JCI Insight, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987